Please login to the form below

Not currently logged in
Email:
Password:

antibody drug conjugate

This page shows the latest antibody drug conjugate news and features for those working in and with pharma, biotech and healthcare.

Immunomedics craters after FDA rejects breast cancer ADC

Immunomedics craters after FDA rejects breast cancer ADC

The US regulator said in its rejection letter on Friday that it wants more information on the manufacturing elements in the marketing application for the antibody-drug conjugate (ADC), delaying the ... It combines SN-38 – an active metabolite of the

Latest news

  • GSK upbeat on its return to oncology market GSK upbeat on its return to oncology market

    Nevertheless, there is expected to be strong performances from its Shingrix vaccine and next-generation respiratory drug Ellipta, which have both been the focus of GSK’s new drive towards commercial ... GSK’s other big hope in oncology is its BCMA

  • ASH18: CAR-T and drugs give new options for multiple myeloma ASH18: CAR-T and drugs give new options for multiple myeloma

    the older drug which isn’t expected be filed for approval until next year. ... There are also updates expected on  GlaxoSmithKline’s anti-BCMA antibody-drug conjugate (ADC) GSK2857916 and Pfizer’s bispecific antibody PF-06863135.

  • BCMA in the spotlight as ASH abstracts drop BCMA in the spotlight as ASH abstracts drop

    Also up for presentation is GlaxoSmithKline’s anti-BCMA antibody-drug conjugate (ADC) GSK2857916 and bispecific antibodies from Amgen (AMG 420) and Pfizer (PF-06863135). ... Among the drug candidates, Amgen’s 35-patient study of AMG 420 revealed an

  • Roche preps new Kadcyla filings after phase 3 trial win Roche preps new Kadcyla filings after phase 3 trial win

    Giving a HER2-targeting drug before surgery in women with early-stage HER2-positive breast cancer has become routine, but doesn’t always clear away all tumour tissue. ... Now, Roche has clinical data showing its antibody-drug conjugate Kadcyla offers a

  • Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3 Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

    Contender could offer potency without dose-limiting toxicities. Daiichi-Sankyo has ambitions to carve out a slice of the HER2 inhibitor market, and is pitting its antibody drug conjugate (ADC) against ... If successful in phase 3, Daiichi-Sankyo’s drug

More from news
Approximately 1 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Finally, there are antibody drug conjugate programmes led out of MedImmune. ... The PARP inhibitor drug prevents BRCA mutation-carrying cells from repairing themselves, causing them to die.

  • Deal Watch January 2018

    enhance blood-brain barrier (BBB) penetration of antibody molecules via the transferrin receptor. ... Also in January Immunomedics sold tiered royalty rights on global net sales of its antibody drug conjugate, sacituzumab govitecan, to Royalty Pharma for

  • Pharma deals continue to slide Pharma deals continue to slide

    Roche has licensed a monoclonal antibody in phase II to Dermira, a dermatology company. ... 250+. Immunogen (US). Jazz (IE, US). Collaboration and option. Phase I haematology-related antibody-drug conjugate plus 2 other projects.

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.

  • Deal Watch April 2016 Deal Watch April 2016

    Its lead compound, Rovalpituzumab tesirine (Rova-T), is a biomarker-specific antibody drug conjugate, in phase I/II targeting cancer stem cell protein DLL3. ... AbbVie (US). Company acquisition. Phase I antibody drug conjugate targeting cancer stem cell

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Glythera has appointed new chief scientific officer Dr Robert Lutz to lead the advancement of the UK-based biotech's antibody drug conjugate portfolio.

  • Glythera appoints Dr Mike Owen Glythera appoints Dr Mike Owen

    He joins as a non-executive director. Antibody drug conjugate development company, Glythera has appointed Dr Mike Owen as its non-executive director. ... At GSK, Owen was responsible for initiating and growing the group’s pre-clinical and clinical

  • ADC Therapeutics expands team ADC Therapeutics expands team

    Appointments preceed its first antibody drug conjugate trials. ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development. ... Oncology drug development company's new team

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics